Genmab A (GMAB) Short-term Investments (2020 - 2025)

Genmab A has reported Short-term Investments for 4 years, with the latest figure at $140.0 million in Q3 2025.

• For the quarter ending Q3 2025, Short-term Investments rose 225.58% year-over-year to $140.0 million; the trailing twelve-month figure through Sep 2025 stood at $140.0 million (up 225.58% YoY), and the FY2025 full-year result was $80.0 million, down 38.46% from the prior year.
• Short-term Investments for Q3 2025 stood at $140.0 million, up from $122.0 million in the prior quarter.
• The five-year high for Short-term Investments was $200.0 million in Q4 2023, with the low at $2.0 million in Q2 2024.
• Historically, Short-term Investments has averaged $91.0 million across 3 years, with a median of $101.0 million in 2025.
• Annual changes were most pronounced in 2024 — Short-term Investments sank 94.5% — and 2025, when it surged 6000.0%.
• Genmab A's Short-term Investments stood at $200.0 million in 2023, then slumped by 94.5% to $11.0 million in 2024, then jumped by 1172.73% to $140.0 million in 2025.
• The last three Short-term Investments figures came in at $140.0 million (Q3 2025), $122.0 million (Q2 2025), and $80.0 million (Q1 2025), per Business Quant data.